The global asthma treatment market size is calculated at USD 28.28 billion in 2024, grew to USD 28.96 billion in 2025, and is predicted to hit around USD 35.93 billion by 2034, poised to grow at a CAGR of 2.42% between 2024 and 2034. The North America asthma treatment market size accounted for USD 11.71 billion in 2024 and is anticipated to grow at the fastest CAGR of 1.88% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Asthma Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Asthma Treatment Market, by Medication Type, 2024-2034
8.1.1. Quick-relief medication
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Long-term control medication
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Asthma Treatment Market, by Route of Administration, 2024-2034
9.1.1. Inhalers
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Prefilled syringes/vials
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. Asthma Treatment Market, by Adjunct Therapy, 2024-2034
10.1.1. LAMA (long-acting muscarinic antagonists)
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. LABA (long-acting beta antagonists)
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. Asthma Treatment Market, by Distribution Channel, 2024-2034
11.1.1. Online pharmacies
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Hospital pharmacies
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Retail pharmacies & drug stores
11.1.3.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Medication (2021-2034)
12.1.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Medication (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Medication (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Medication (2021-2034)
12.2.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Medication (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Medication (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Medication (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Medication (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Medication (2021-2034)
12.3.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Medication (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Medication (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Medication (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Medication (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Medication (2021-2034)
12.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Medication (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Medication (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Medication (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Medication (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Medication (2021-2034)
12.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Medication (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Medication (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2034)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.1. AstraZeneca
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Teva Pharmaceutical Industries Ltd.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. GlaxoSmithKline plc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Boehringer Ingelheim International GmbH
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Roche Holding AG / Novartis AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Merck & Co., Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Koninklijke Philips N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Sanofi-Aventis SA
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. MundiPharma
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample